Novo-Nordisk A/S
Veridion Score
Composite trend over time
Why is NVO moving today?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for NVO.
NVO insider activity
Novo-Nordisk A/S
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for NVO.
NVO contract awards, year to date.
Public federal awards linked to this ticker.
NVO lobbying filings, year to date.
Registered lobbying filings matched to Novo-Nordisk A/S.